PARP Inhibitor Market, by Drug Type (Niraparib (Zejula), Olaparib (Lynparza), Rucaparib (Rubraca), and Talazoparib (Talzenna)), by Application (Ovarian Cancer, Breast Cancer, and Others), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies) and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis 2019 - 2027

  • Published On : Sep 2019 |
  • Pages : 147 Pages |
  • Format : CMI Insight PPT Format CMI Insight PDF Format

Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Market – Market Insights

Poly ADP-Ribose Polymerase (PARP) inhibitors are long chain containing 17 enzymes that combine several (poly) units of ADP-ribose in a chain and transfer them to the target proteins. This helps to restore DNA when it is damaged by many factors such as exposure to UV  radiation, some anti-cancer drugs and others. PARP inhibitors block an enzyme critical to the repair of single stranded breaks in the DNA. Inhibition of this DNA repair enzyme can lead to cell death, particularly in cancer cells that carry deficiency of other DNA repair pathways.

Furthermore, PARP inhibitors play an effective maintenance role in current cancer treatments owing to their therapeutic effect on ovarian cancer. According to the World Ovarian Cancer Coalition statistics of 2018, there are around 600,000 women diagnosed with an ovarian cancer for a period of 5 years.

The global PARP (Poly ADP-Ribose Polymerase) inhibitor market was valued at US$ 887.7 Mn in 2018, and is expected to exhibit a CAGR of 32.4% over the forecast period (2019–2027).

Figure 1. Global PARP Inhibitor Market Value (US$ Mn), by Region, 2018

PARP Inhibitor  | Coherent Market Insights

Source: Coherent Market Insights Analysis (2019)

Increasing research and development activities by market players are expected to increase application of PARP inhibitors

Currently, PARP is indicated for treatment of ovarian cancer and breast cancer. However, researchers are focused on expanding the application of PARP inhibitors. For instance, in December 2018, University of Michigan Rogel Cancer Center planned Phase II trials of the investigational drug combination of olaparib and AZD6738 for treatment of metastatic castration-resistant prostate cancer.

In May 2019, Clovis Oncology, Inc., in collaboration with Bristol-Myers Squibb Company and Foundation Medicine Inc., initiated Phase II studies to evaluate rucaparib in combination with nivolumab in patients with high-grade serous or endometrial ovarian cancer. The study is expected to be completed in January 2022.

In April 2019, Pfizer, Inc., received positive feedback from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) for TALZENNA (talazoparib), an oral poly (ADP-ribose) polymerase (PARP) inhibitor indicated for treatment in locally advanced (LA) or metastatic breast cancer (MBC).

Moreover, delays in regulatory approvals can result in delayed marketing of the product, which can affect the revenue of the manufacturer. Similarly, delay in post approval of the drug for other therapeutic indications results in increasing clinical trials costs and can impact the labelling and approval status of currently marketed products. Thus, these factors are expected to hamper the PARP inhibitor market growth.

 

Figure 2. Global PARP Inhibitor Market Share (%), by Application

PARP Inhibitor  | Coherent Market Insights

Source: Coherent Market Insights Analysis (2019)  

Increasing approvals of innovative drugs molecules in PARP inhibitor market

In the recent past, several key players in the market have received approvals for their PARP inhibitor molecules which is expected to create a lucrative environment for growth of global  PARP inhibitors market in the near future.

In January 2018, AstraZeneca PLC received approval from the Japanese Ministry of Health, Labour and Welfare for Lynparza (olaparib) tablets indicated as maintenance therapy for patients with platinum-sensitive relapsed ovarian cancer. Lynparza is the first approved poly ADP-ribose polymerase (PARP) inhibitor in Japan.

In October 2018, Pfizer, Inc., received the U.S. Food and Drug Administration approval for TALZENNA (talazoparib), a (PARP) inhibitor indicated for treatment in locally advanced (LA) or metastatic breast cancer (MBC).

In April 2018, Clovis Oncology, Inc. received the U.S. Food and Drug Administration approval for Rubraca (rucaparib) tablets, a (PARP) inhibitor indicated for treatment of recurrent ovarian cancer.

Moreover, several key players in the market are focusing on strategic mergers and acquisition strategies for expanding their product portfolios. For instance, in January 2019, GlaxoSmithKline plc, acquired TESARO, Inc. for around US$ 5.1 billion. TESARO, Inc. has developed the approved product Zejula (niraparib), an oral poly ADP ribose polymerase (PARP) inhibitor indicated for ovarian cancer. The acquisition is expected to increase the application of Zejula for multiple cancer treatments.

Key Players

Major players operating in the global PARP inhibitor market include AstraZeneca Plc., Johnson & Johnson, GlaxoSmithKline Plc., Pfizer, Inc., Clovis Oncology Inc., AbbVie Inc., Bristol Myers Squibb, Merck KGaA, Genentech, Inc., Artios Pharma, Repare Therapeutics Inc., Sierra Oncology, Inc., KaryopharmTherapeutics Inc., Ono Pharmaceutical Co., Ltd., Jiangsu Hengrui Medicine Co., Ltd.

PARP inhibitors are drugs which inhibit the enzyme called poly ADP ribose polymerase (PARP). PARP inhibitors are developed for treating several diseases, the most important one is cancer. Several types of cancers rely on PARP enzymes than regular cells, which makes these inhibitors an effective mode of treating cancers. PARP inhibitors are used to treat a subset of ovarian cancer. Currently, 3 PARP inhibitors have been approved for use in ovarian cancer patients who have undergone 3 or more prior lines of chemotherapy. Olaparib (Lynpraza) was the first PARP inhibitor to receive approval in 2014 followed by Rucaparib in 2016, and Niraparib in 2017. Furthermore, several PARP inhibitors which are currently in later stages of development have shown promising results in recently released clinical trials data.

Market Dynamics

The global PARP inhibitors market is driven by product developments, increasing number of positive results, as well as availability of novel therapies in the market. Companies such as Pfizer, AstraZeneca and Tesaro, Inc. have a robust pipeline of PARP inhibitors and several ongoing trials of products are scheduled to be completed by 2022. These factors are expected to propel growth of the market over the forecast period. However, side effects associated with the drugs and drug resistance among patients are some of the factors that are expected to hamper the market growth.

Key features of the study:

  • This report provides in-depth analysis of the global PARP inhibitor market and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2019–2027), considering 2018 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends,  regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the global PARP inhibitor market based on the following parameters – company overview, financial performance, product portfolio, market presence, distribution strategies, key developments, strategies, and future plans
  • Key companies covered as a part of this study include AstraZeneca Plc., Johnson & Johnson, GlaxoSmithKline plc., Pfizer, Inc., Clovis Oncology Inc., AbbVie Inc., Bristol - Myers Squibb, Merck KGaA, Genentech, Inc., Repare Therapeutics Inc., Sierra Oncology, Inc., Karyopharm Therapeutics Inc., Ono Pharmaceutical Co., LTD., and Jiangsu Hengrui Medicine Co., Ltd.
  • Insights from this report would allow marketers and management authorities of companies to make informed decisions regarding future product launches, technology up-gradation, market expansion, and marketing tactics
  • The global PARP inhibitor market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global PARP inhibitor market

Detailed Segmentation:

  • Global PARP inhibitor Market, By Drug Type:
    • Niraparib (Zejula)
    • Olaparib (Lynparza)
    • Rucaparib (Rubraca)
    • Talazoparib (Talzenna)
  • Global PARP inhibitor Market, By Application:
    • Ovarian Cancer
    • Breast Cancer
  • Global PARP inhibitor Market, By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • Global PARP inhibitor Market, By Region:
    • North America
      • By Drug Type:
        • Niraparib (Zejula)
        • Olaparib (Lynparza)
        • Rucaparib (Rubraca)
        • Talazoparib (Talzenna)
      • By Application:
        • Ovarian Cancer
        • Breast Cancer
      • By Distribution Channel:
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country:
        • U.S.
        • Canada
    • Latin America
      • By Drug Type:
        • Niraparib (Zejula)
        • Olaparib (Lynparza)
        • Rucaparib (Rubraca)
        • Talazoparib (Talzenna)
      • By Application:
        • Ovarian Cancer
        • Breast Cancer
      • By Distribution Channel:
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country:
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Europe
      • By Drug Type:
        • Niraparib (Zejula)
        • Olaparib (Lynparza)
        • Rucaparib (Rubraca)
        • Talazoparib (Talzenna)
      • By Application:
        • Ovarian Cancer
        • Breast Cancer
      • By Distribution Channel:
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country:
        • Germany
        • U.K.
        • France
        • Italy
        • Spain
    • Asia Pacific
      • By Drug Type:
        • Niraparib (Zejula)
        • Olaparib (Lynparza)
        • Rucaparib (Rubraca)
        • Talazoparib (Talzenna)
      • By Application:
        • Ovarian Cancer
        • Breast Cancer
      • By Distribution Channel:
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country:
        • China
        • India
        • Japan
        • Australia
        • South Korea
        • ASEAN
        • Rest of Asia Pacific
    • Middle East
      • By Drug Type:
        • Niraparib (Zejula)
        • Olaparib (Lynparza)
        • Rucaparib (Rubraca)
        • Talazoparib (Talzenna)
      • By Application:
        • Ovarian Cancer
        • Breast Cancer
      • By Distribution Channel:
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country:
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • By Drug Type:
        • Niraparib (Zejula)
        • Olaparib (Lynparza)
        • Rucaparib (Rubraca)
        • Talazoparib (Talzenna)
      • By Application:
        • Ovarian Cancer
        • Breast Cancer
      • By Distribution Channel:
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country:
        • South Africa
        • Central Africa
        • North Africa
  • Company Profiles
    • AstraZeneca Plc.,*
      • Company Overview
      • Material Portfolio
      • Financial Performance
      • Key Highlights
    • Johnson & Johnson
    • GlaxoSmithKline plc.
    • Pfizer, Inc.,
    • Clovis Oncology Inc.
    • AbbVie Inc.
    • Bristol - Myers Squibb
    • Merck KGaA
    • Genentech, Inc.
    • Repare Therapeutics Inc.
    • Sierra Oncology, Inc.
    • Karyopharm Therapeutics Inc.
    • Ono Pharmaceutical Co. Ltd.,
    • Jiangsu Hengrui Medicine Co., Ltd.

“*” marked represents similar segmentation in other categories in the respective section.

Table of Contents

  1. Research Objectives and Assumptions
    • Research Objectives
    • Assumptions
    • Abbreviations
  2. Market Purview
    • Report Description
      • Market Definition and Scope
    • Executive Summary
      • Market Snippet, By Drug Type
      • Market Snippet, By Application
      • Market Snippet, By Distribution Channel
      • Market Snippet, By Region
    • Coherent Opportunity Map (COM)
  3. Market Dynamics, Regulations, and Trends Analysis
    • Market Dynamics
      • Drivers
      • Restraints
      • Market Opportunities
    • Impact Analysis
    • Market Trends
    • Key Developments
    • Pipeline Analysis
    • Regulatory Scenario
    • Pricing Analysis
    • Merger and Acquisition Scenario
    • PEST Analysis
    • Epidemiology
  4. Global PARP Inhibitor Market, By Drug Type, 2016 – 2027, (US$ Mn)
    • Introduction
      • Market Share Analysis, 2019 and 2027 (%)
      • Y-o-Y Growth Analysis, 2017 – 2027
      • Segment Trends
    • Niraparib (Zejula)
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
    • Olaparib (Lynparza)
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
    • Rucaparib (Rubraca)
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
    • Talazoparib (Talzenna)
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
  5. Global PARP Inhibitor Market, By Application, 2016 – 2027, (US$ Mn)
    • Introduction
      • Market Share Analysis, 2019 and 2027 (%)
      • Y-o-Y Growth Analysis, 2017 – 2027
      • Segment Trends
    • Ovarian Cancer
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
    • Breast Cancer
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
  6. Global PARP Inhibitor Market, By Distribution Channel, 2016 – 2027, (US$ Mn)
    • Introduction
      • Market Share Analysis, 2019 and 2027 (%)
      • Y-o-Y Growth Analysis, 2017 – 2027
      • Segment Trends
    • Hospital Pharmacies
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
    • Retail Pharmacies
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
    • Online Pharmacies
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
  7. Global PARP Inhibitor Market, By Region, 2016 – 2027, (US$ Mn)
    • Introduction
      • Market Share Analysis, By Region, 2019 and 2027 (%)
      • Y-o-Y Growth Analysis, For Regions, 2017–2027
    • North America
      • Market Size and Forecast, By Drug Type, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Application, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Distribution Channel, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Country, 2016 – 2027, (US$ Mn)
        • U.S.
        • Canada
    • Latin America
      • Market Size and Forecast, By Drug Type, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Application, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Distribution Channel, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Country, 2016 – 2027, (US$ Mn)
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Europe
      • Market Size and Forecast, By Drug Type, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Application, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Distribution Channel, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Country, 2016 – 2027, (US$ Mn)
        • Germany
        • U.K.
        • France
        • Italy
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • Market Size and Forecast, By Drug Type, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Application, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Distribution Channel, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Country, 2016 – 2027, (US$ Mn)
        • China
        • India
        • Japan
        • Australia
        • South Korea
        • ASEAN
        • Rest of Asia Pacific
    • Middle East
      • Market Size and Forecast, By Drug Type, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Application, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Distribution Channel, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Country, 2016 – 2027, (US$ Mn)
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • Market Size and Forecast, By Drug Type, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Application, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Distribution Channel, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Country, 2016 – 2027, (US$ Mn)
        • South Africa
        • Central Africa
        • North Africa
  8. Competitive Landscape
    • Heat Map Analysis
    • Market Share Analysis
      • AstraZeneca Plc.,*
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Johnson & Johnson
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • GlaxoSmithKline plc.
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Pfizer, Inc.
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Clovis Oncology Inc.
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • AbbVie Inc.
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Bristol - Myers Squibb
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Merck KGaA
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Genentech, Inc.
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Repare Therapeutics Inc.
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Sierra Oncology, Inc.
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Karyopharm Therapeutics Inc.
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Ono Pharmaceutical Co. Ltd.,
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Jiangsu Hengrui Medicine Co., Ltd.
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
    • Analyst Views
  9. Section
    • References
    • Research Methodology
    • About Us and Sales Contact

*Browse 36 market data tables and 30 figures on "PARP Inhibitor Market” - Global forecast to 2027.

Choose License Type

"How Can I Help You" ?

Finding it difficult to find the research that would cater to your business demands? Give us a chance to help you. One of our Research Consultants will connect to provide a customized solution.

[email protected]

Key Benefits

  • Custom Research Solution

    Talk to our research consultant to design an exclusive report as per your research needs.

  • Customer Fulfilment

    We aim to fulfil client's research demands with tailored research solutions.

  • Quick Turnaround Time Reports

    We aim to provide research studies in quickest turnaround time and in a much cost effective manner.

  • 360-degree Approach

    We cover each industry from supply and demand side with an aim to provide a most holistic research study.

  • Assured Quality

    We strive to provide most accurate and reliable research findings in our research reports.